As a result, that also drives just a ton of leverage and efficiency across the business. And so over time, what we would expect is, we would start to get leverage on the marketing line as well. Realistically, we’re probably looking at, at least probably a 5-year plus horizon, I’d say, 5 years to 10 years to truly probably hit the that type of concept. But really, it’s going to be a straight off between how we make the investments versus how we continue to see our base evolve and mature.
Q €“ Korinne Wolfmeyer: Fair enough. Thank you.
Operator: And we’ll go next now to Ivan Feinseth at Tigress Financial.
Ivan Feinseth: Thank you for taking my questions and congratulations on another huge year. I have two questions. In your projections going into 2025, does that 1.2 billion include any possible M&A or that would be if you were to make an acquisition be in additional to that?
Andrew Dudum: Thanks, Ivan, for the question. This is really representative of the organic trajectory of the business. So, it does not take into consideration any opportunities on the M&A side that might pop-up in the next couple of years.
Ivan Feinseth: Are they not giving specifics, but let’s say, what would be, let’s say, some of the other areas that you would like to expand into?
Andrew Dudum: From a category standpoint, I think on the investor presentation that we released, that’s up on the investor website right now. We outlined a couple of prospective markets that the team is really energized by. On the men’s health side, this is things like prostate health, testosterone. On the women’s health side, you’re talking about things like menopause and digestion. On mental health, there’s quite a bit in €“ still to unlock in customers struggling with insomnia, PTSD. And then in more general health, pain management, fertility concerns for men and women, weight and metabolic health, cardiovascular, diabetes. I know that’s a lot, but I think the honest answer is, those are all categories the team is looking at and spending a lot of time in.
And for us, it’s really not a question of if we’re going to launch in any of these categories. It’s really just a question of when and how, right. I think we have a desire to bring to market products and services that truly are innovative and truly personalized. And so that means not necessarily rushing out the door with a new medicine once it’s been approved, it means actually thinking about how we deliver that to patients in a way that’s improving their outcomes and their preferences and ultimately, the relationship we have with them. And so, those are a lot of categories, but I think it’s just a matter of time between us and launching them. And it’s just a question of how we bring them into market in a way that we feel is very much representative of the Hims & Hers approach.
Ivan Feinseth: Okay. And my other question is, like since bringing on Kristen Bell as spokesperson, what kind of impact have you seen or how do you measure that? And then, like what were some other types of people €“ like types of areas in similar roles that you would look to expand into?
Andrew Dudum: Yes, it’s a great question. I think Kristen is a unique example in that, she is so authentically and courageously speaks to her struggles over the years with depression, anxiety. And I think that authenticity is really powerful for men and women to hear, especially for categories that are, in a lot of ways, full of shame and highly stigmatized. And despite the fact that huge portions of the country suffer from them, very few percent of those people actually go and get treated. And so, we’ve seen really strong results on the brand building side for Kristen. A lot of people are seeing that message, and it’s resonating with them and coming and be encouraged to evaluate solutions for them. And so for me, I really think of our biggest competitor as somebody who is just reluctant to take that first step, right?
